Just Published

Treatment-Resistant Depression as a Dynamic Continuum
Clinical Pearls

Treatment-Resistant Depression as a Dynamic Continuum

November 6, 2026

Seven questions on treatment-resistant depression: early recognition, adequate trials, mechanistic sequencing, and when to refer.
Gastrointestinal Adverse Events After 5 and 52 Weeks of Xanomeline-Trospium in Inpatients and Outpatients
Clinical Pearls

Gastrointestinal Adverse Events After 5 and 52 Weeks of Xanomeline-Trospium in Inpatients and Outpatients

November 6, 2026

When gastrointestinal events appear with xanomeline-trospium: onset, duration, and discontinuation across 5-week and 52-week trials.
Efficacy Outcomes After 5 and 52 Weeks of Xanomeline-Trospium in Inpatients and Outpatients
Clinical Pearls

Efficacy Outcomes After 5 and 52 Weeks of Xanomeline-Trospium in Inpatients and Outpatients

November 6, 2026

Two trials, two populations: xanomeline-trospium PANSS and CGI-S outcomes at 5 weeks in inpatients and 52 weeks in outpatients, and why they differ.
Margaret Sibley, PhD, on Fluctuating ADHD Across the Lifespan in the MTA Study
JCP Podcast 🎧 Podcast

Margaret Sibley, PhD, on Fluctuating ADHD Across the Lifespan in the MTA Study

November 6, 2026

In this JCP Podcast episode, Margaret Sibley, PhD, discusses her article on fluctuating ADHD in the Multimodal Treatment of ADHD study. She describes how symptom trajectories, comorbidities, and environmental…
EMERGENT-5 Side Effects Resembled Those in the 5-Week Trials
news

EMERGENT-5 Side Effects Resembled Those in the 5-Week Trials

November 5, 2026

Long-term xanomeline-trospium side effects in schizophrenia resembled those in short-term trials, but the lack of a comparator limits interpretation.
PCC
Adrenal Cortex Supplement Use During BZD Withdrawal
Case Report

Adrenal Cortex Supplement Use During BZD Withdrawal

November 5, 2026

The authors report the case of a 31-year-old man who regularly used a bovine-derived adrenal cortex supplement during benzodiazepine withdrawal
, ,

Explore
By Topic

View all topics
Addiction Anxiety Bipolar Disorder Depression (MDD) Movement Disorders Neurology Obsessive-Compulsive and Related Disorders Psychedelics Psychopharmacology Schizophrenia/Schizoaffective Disorders Tardive Dyskinesia

Recent Features

Neural network illustration exploring psychedelic therapy mechanisms
Psychiatric researcher Nina Schooler, PhD, expert in schizophrenia care
Promotional graphic shows Biostats Made Simple by Dr. Andrade, promoting mastering statistics for clinical decisions.
The Journal of Clinical Psychiatry logo with person reading research publication

Original Research

PCC
Prescription Patterns in Canadian Operational Stress Injury Clinics: An In-Depth Examination of Posttraumatic Stress Disorder Treatment Practices
Original Research

Prescription Patterns in Canadian Operational Stress Injury Clinics: An In-Depth Examination of Posttraumatic Stress Disorder Treatment Practices

November 5, 2026

The findings highlight the challenges of applying guideline-based care to patients with chronic, complex PTSD and underscore the need for further research on sequenced and combined pharmacologic strategies.
, , , et al
PCC
Efficacy of Lumateperone 42 mg in MDD
Original Research

Efficacy of Lumateperone 42 mg in MDD

November 3, 2026

, , , et al
JCP
Sibling Psychiatric Diagnoses and Risk of Postpartum Psychosis
Original Research

Sibling Psychiatric Diagnoses and Risk of Postpartum Psychosis

November 2, 2026

The strongest associations were observed for sister’s postpartum psychosis, cyclothymia, schizoaffective disorder, and bipolar disorder.
, , , et al

The Journal of Clinical Psychiatry

The Journal of Clinical Psychiatry is a leader in peer-reviewed articles on mental health topics for psychiatrists and medical professionals. Now featuring The JCP Podcast: conversations with experts exploring the research shaping clinical care.  

EXPLORE JCP
JCP
Treating Alzheimer’s Agitation, Not Just Quieting It with Pierre N. Tariot, MD
Podcast

Treating Alzheimer’s Agitation, Not Just Quieting It with Pierre N. Tariot, MD

November 3, 2026

Pierre N. Tariot, MD, on agitation in Alzheimer’s disease: why sedation is not efficacy, primary care assessment, and the two FDA-approved treatment options.
,
JCP
Establishing the Clinical Role of Digital Therapeutics in Major Depressive Disorder Treatment: A Consensus Panel Perspective
Academic Highlights ▶ Video

Establishing the Clinical Role of Digital Therapeutics in Major Depressive Disorder Treatment: A Consensus Panel Perspective

November 2, 2026

This consensus panel report discusses the clinical role of digital therapeutics in major depressive disorder, with four consensus statements on evaluating, selecting, and implementing them within stepped care, including…
, , , et al

Explore Special Sections from JCP

Focus on Childhood and Adolescent Mental Health Early Career Psychiatrists Focus on Geriatric Psychiatry Focus on Psychosis Focus on Psychotherapy Focus on Suicide Focus on Women’s Mental Health

The Primary Care Companion for CNS Disorders

The Primary Care Companion for CNS Disorders seeks to advance the clinical expertise of primary care physicians and other health care professionals who treat patients with mental and neurologic illnesses.

View PCC Articles
PCC
Specific Phobia to White Clouds With Acrophobia
Case Report

Specific Phobia to White Clouds With Acrophobia

November 3, 2026

The authors report a case of nephophobia co-occurring with longstanding acrophobia in a 38-year-old man.
,
PCC
Oral Budesonide-Induced Psychosis
Case Report

Oral Budesonide-Induced Psychosis

October 29, 2026

A 66-year-old woman developed psychosis 1 week after beginning oral budesonide, which resolved with steroid taper
,

ASCP - American Society of Clinical Psychopharmacology logo

Read articles from ASCP Corner

ASCP Corner

Insightful. Evidence-based. Human-centered.

Listen Now
Psychiatrist Steven Berkowitz, MD, discusses psychedelic medicine for trauma treatment

Subscribe to read
more articles

Subscribe